Hospira best champion for US Biosimilars??

Hospira is positioning itself as THE US Biosimilars company. (website posting below)

With all of the legal and quality issues they have going on (see How many straws article link below), can they really be trusted with this role... or is it self-appointed?

http://hospira.com/en/about_hospira/government_affairs/biosimilars_policy_positions/index

….. Hospira is engaged with governments and major stakeholders in the United States and around the world, resulting in stronger, more informed public policies in numerous countries. These efforts are guided by Hospira’s commitment to going beyond basic regulatory compliance and implementing the highest standards of corporate accountability, transparency, integrity and responsibility….... Currently, Hospira is working to ensure that regulations and policies in the United States support the introduction and successful adoption of biosimilar drugs by mid-decade…..


http://pharmaleaders.net/how-many-straws-after-60-million-settlement-for-poor-manufacturing-quality-hospira-warned-by-fda-then-assessed-punitive-damages-for-firing-whistle-blower/

The author needs to add that in the $60 million agreement, as part of the settlement, Hospira agreed to make changes so that executives in charge of quality will meet regularly with board members. So Ball has to be babysat by the board. Does this mean that the next FDA warning letter is to be addressed to the Hospira BOD members???

 

and...? sooo....? feeling a little competitive within the emerging Bilosimilar market eh?
and you need conversation from the world of CP? Please Lighten up

 

Interesting perspective

 

If the limits of your Humira defense strategy are raising subtle doubts against manufacturers, your shareholders should demand better.

 

just you on here you idiot asswipe

 

exactly! Note to those who hire outside firms to conduct CI market research. It aint only secondary research these greedy bastards prowl through to social media with a magnifier for...you are paying far too much for your contracts where these rip off artists can only bait for conversation on CP. Biosimilar project managers please take note.